3D vs 2D-laparoscopy for Rectocele and Rectal Prolapse Correction: a Prospective, Randomized, Single Center Study

NCT ID: NCT04817150

Last Updated: 2021-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-10

Study Completion Date

2022-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim is to compare proximate and remote results of 3D and conventional 2D laparoscopic interventions in terms of efficacy and safety in treatment of symptomatic rectocele and rectal prolapse.

This is a prospective randomized comparative study in parallel groups conducted in single Colorectal unit. Inclusion criteria: female patients with stage 3 rectocele (3-4 POP-Q \[pelvic organ prolapse quantification\] grade) and/or full-thickness rectal prolapse.

Intervention - laparoscopic ventral rectopexy. The primary outcome is objective cure rate of pelvic prolapse. Secondary outcomes include obstructive defecation and incontinence symptoms according to Wexner and Cleveland Clinic scales, and satisfaction according to Patient Global Impression of Improvement questionnaire. Operative times, intraoperative blood loss, length of hospital stay, postop pain severity, urinary incontinence, as well as surgical and mesh complications are also assessed.

The specific point of interest in this study is surgeon's tiredness after the operation assessed with Profile of Mood States questionnaire.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectocele; Female Rectocele and Incomplete Uterine Prolapse Rectocele and Complete Uterovaginal Prolapse Rectal Prolapse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

a prospective randomized comparative study in parallel groups
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Outcomes are assessed by 2 independent blinded coloproctologists

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

3D-laparoscopy

patients who underwent 3D laparoscopic ventral rectopexy

Group Type EXPERIMENTAL

Laparoscopic ventral mesh rectopexy

Intervention Type PROCEDURE

Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore

2D-laparoscopy

patients who underwent conventional 2D laparoscopic ventral rectopexy

Group Type ACTIVE_COMPARATOR

Laparoscopic ventral mesh rectopexy

Intervention Type PROCEDURE

Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Laparoscopic ventral mesh rectopexy

Conventional laparoscopic ventral mesh rectopexy, as first described by D'Hoore

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* stage 3 rectocele (3-4 POP-Q grade) and/or full-thickness rectal prolapse
* age 18-70 y.o.

Exclusion Criteria

* severe concomitants chronic diseases (American Society of Anesthesiologists class III - IV),
* ongoing oncological diseases,
* ongoing hematological diseases,
* ongoing inflammatory diseases of the colon and pelvic organs,
* pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alexander Khitaryan

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alexander Khitaryan

Professor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Private Healthcare Institution Clinical Hospital "RGD-Medicine" Rostov-on-Don"

Rostov-on-Don, , Russia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Russia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anastasiya Golovina

Role: CONTACT

+79518319720

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Anastasiya Golovina, Dr

Role: primary

+79518319720

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LARC1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.